Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gold, R.
Right arrow Articles by Linington, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gold, R.
Right arrow Articles by Linington, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 125, No. 7, 1425-1427, July 2002
© 2002 Guarantors of Brain

Editorial

Devic’s disease: bridging the gap between laboratory and clinic

Ralf Gold1 and Christopher Linington2

1 Department of Neurology Clinical Research Group for Multiple Sclerosis and Neuroimmunology University of Würzburg, Germany 2 Department of Neuroimmunology Max Planck Institute for Neurobiology Martinsried, Germany

The first 10% of the full text of this article appears below.

Our first insights into the pathogenesis of multiple sclerosis were obtained following developments in histopathology in the late 19th Century. More than a century later, despite the advanced molecular tools that are now available, significant progress in unravelling the pathogenesis of multiple sclerosis is still very much dependent on similar approaches. The inaccessibility of the CNS for direct study, and the clinical and genetic heterogeneity of multiple sclerosis combine to make the study of multiple sclerosis difficult to say the least (Compston et al., 1998Go). Recently Hans Lassmann and his colleagues Lucchinetti and Brück proposed a classification for multiple sclerosis lesions based on molecular histopathological findings from diagnostic biopsies and autopsies (Lassmann et al., 2001Go), an approach similar . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Mult SclerHome page
G.J.D. Hengstman, P. Wesseling, C.W.G.M. Frenken, and P.J.H. Jongen
Neuromyelitis optica with clinical and histopathological involvement of the brain
Multiple Sclerosis, June 1, 2007; 13(5): 679 - 682.
[Abstract] [PDF]

Home page
 Rheumatology (Oxford)Home page
F. Falcini, S. Trapani, L. Ricci, M. Resti, G. Simonini, and M. de Martino
Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment
Rheumatology, July 1, 2006; 45(7): 913 - 915.
[Full Text] [PDF]

Home page
 Mult SclerHome page
R Bergamaschi, S Tonietti, D Franciotta, E Candeloro, E Tavazzi, G Piccolo, A Romani, and V Cosi
Oligoclonal bands in Devic's neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations
Multiple Sclerosis, February 1, 2004; 10(1): 2 - 4.
[Abstract] [PDF]

Home page
 BrainHome page
R. Bergamaschi
Glatiramer acetate treatment in Devic's neuromyelitis optica
Brain, June 1, 2003; 126(6): E1 - E1.
[Full Text] [PDF]

Home page
 BrainHome page
R. Gold and C. Linington
Reply
Brain, June 1, 2003; 126(6): E1 - E1.
[Full Text] [PDF]